Broken String Biosciences: Laurence Reid, Brad Crutchfield

Gene editing company Broken String Biosciences has appointed Laurence Reid and Brad Crutchfield to its board of directors. 

Reid joins the board as chairman. He was previously CEO at Decibel Therapeutics and Warp Drive Bio. He has also held executive positions at Alnylam Pharmaceuticals, Ensemble Discovery, and Millenium Pharmaceuticals. He is also a board member at other biotech companies and nonprofit organizations. 

Crutchfield was most recently chief commercial officer at 10x Genomics. He was also senior VP of life sciences at Qiagen; VP and general manager of Europe, Middle East and Africa at Illumina; and president of the life science group at Bio-Rad Laboratories. He also sits on the boards of Pixelgen Technologies, Partillion Bioscience, and S2 Genomics.